Advertisement

Therapeutic Monitoring and Prediction of the Efficacy of Neurotrophic Therapy in Patients with Amnestic-Type Mild Cognitive Decline Syndrome

  • S. I. GavrilovaEmail author
  • O. M. Volpina
  • I. V. Kolykhalov
  • Ya. B. Fedorova
  • N. D. Selezneva
  • E. V. Ponomareva
  • D. O. Koroev
  • A. V. Kamynina
Article

Objectives. Therapeutic monitoring and evaluation of the efficacy of neurotrophic therapy in patients with amnestic-type mild cognitive decline syndrome (aMCI) were performed in a model using courses of cerebrolysin. Materials and methods. A total of 19 elderly patients meeting the diagnostic criteria for aMCI syndrome were studied. All patients received treatment with cerebrolysin: 20 intravenous dropwise infusions of 30 ml in 100 ml of physiological saline. Treatment efficacy was evaluated using psychometric tests and scales (CGI, MMSE, MoCA, MDRS, clock drawing test, BNT, 10-word memory test, 10-word delayed reproduction test, forward number naming test, backward number naming test) at study weeks 0, 4, 10, and 26. Levels of autoantibodies to p75 neurotrophin receptor were determined by solid-phase immnoenzyme analysis. Serum from 19 patients was studied before cerebrolysin treatment (day 0) and at weeks 10 and 26 after treatment initiation. Results and conclusions. Patients with aMCI had increased levels of autoantibodies to p75 fragment, with gradual decreases by 5.5 months of cerebrolysin treatment, indicating that this can potentially be used as a biomarker for long-term therapeutic efficacy. The modified p75 receptor fragment 155–164, assayed in patients’ serum, may provide an effective tool for monitoring and predicting the efficacy of long-term neurotrophic therapy.

Keywords

elderly age mild cognitive decline dementia autoantibodies to p75 fragment neurotrophic therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. Franceschi, M. Comola, R. Nemni, et al., “Neuron-binding antibodies in Alzheimer’s disease and Down’s syndrome,” J. Gerontol., 44, 128–130 (1989),  https://doi.org/10.1093/geronj/44.4.m128.Google Scholar
  2. 2.
    R. G. Nagele, P. M. Clifford, G. Siu, et al., “Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta1-42 deposition,” J. Alzheimers Dis., 25, No. 4, 605–622 (2011),  https://doi.org/10.3233/JAD-2011-110098.Google Scholar
  3. 3.
    S. Ray, M. Britschgi, C. Herbert, et al., “Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins,” Nat. Med., 13, 1359–1362 (2007),  https://doi.org/10.1038/nm1653.Google Scholar
  4. 4.
    V. K. Singh, “Studies of neuroimmune markers in Alzheimer’s disease,” Mol. Neurobiol., 9, No. 1–3, 73–81 (1994),  https://doi.org/10.1007/BF02816106.Google Scholar
  5. 5.
    B. Chakravarthy, M. Ménard, S. Ito, et al., “Hippocampal membrane-associated p75NTR levels are increased in Alzheimer’s disease,” J. Alzheimers Dis., 30, 675–684 (2012),  https://doi.org/10.1007/BF02816106.Google Scholar
  6. 6.
    M. Kolarova, J. Ricny, A. Bartos, et al., “Naturally occurring antibodies against synthetic fragment of neurotrophin receptor P75 in sera of cognitively impaired patients,” SOJ Immunology, 4, No. 1, 1–4 (2016),  https://doi.org/10.15226/2372-0948/4/2/00149.Google Scholar
  7. 7.
    O. M. Volpina, N. I. Medvinskaya, A. V. Kamynina, et al., “Immunization with a synthetic fragment of the p75 neurotrophin receptor prevents loss of spatial memory and decreases β-amyloid levels in mice with experimentally induced Alzheimer’s disease,” Bioorgan. Khim., 40, No. 4, 451–457 (2014),  https://doi.org/10.7868/S0132342314040150.Google Scholar
  8. 8.
    A. V. Sadin, N. Yu. Zhidomorov, I. V. Gogoleva, et al., “Studies of the neuroregenerative action of cerebrolysin in traumatic brain injury,” Zh. Nevrol. Psikhiat., 113, No. 4, 57–60 (2013).Google Scholar
  9. 9.
    R. A. Vazquez-Roque, K. Ubhi, E. Masliah, and G. Flores, “Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat,” Synapse, 68, No. 1:31–38 (2013),  https://doi.org/10.1002/syn.21718.Google Scholar
  10. 10.
    H. S. Sharma, A. Sharma, H. Mossler, and D. F. Muresanu, “Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication,” Int. Rev. Neurobiol., 102, 249–276 (2012),  https://doi.org/10.1016/B978-0-12-386986-9.00010-7.Google Scholar
  11. 11.
    L. Zhang, M. Chopp, D. H. Meier, et al., “Sonic hedgehog signaling pathway mediates cerebrolysin improved neurological function after stroke,” Stroke, 44, No. 7, 1965–1972 (2013),  https://doi.org/10.1161/STROKEAHA.111.000831.Google Scholar
  12. 12.
    G. S. Georgy, N. N. Nassar, H. A. Mansour, and D. M. Abdallah, “cerebrolysin ameliorates cognitive deficits in type III diabetic rats,” PLoS One, 8, No. 6, 64847 (2013),  https://doi.org/10.1371/journal.pone.0064847.Google Scholar
  13. 13.
    S. Harada, Y. Yamazaki, and S. Tokuyama, “Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain? derived neurotrophic factor,” J. Pharmacol. Exp. Ther., 344, No. 1, 276–285 (2013),  https://doi.org/10.1124/jpet.112.199604.Google Scholar
  14. 14.
    K. Ubhi, E. Rockenstein, R. Vazquez-Roque, et al., “cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease,” J. Neurosci. Res., 91, No. 2, 167–177 (2012),  https://doi.org/10.1002/jnr.23142.Google Scholar
  15. 15.
    F. Alcantara-Gonzalez, C. R. Mendoza-Perez, N. Zaragoza, et al., “Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice,” Synapse, 66, No. 11, 938–949 (2012),  https://doi.org/10.1002/syn.21588.Google Scholar
  16. 16.
    M. Reiner, M. Brunnbayer, A. Dunky, et al., “Therapeutic results with cerebrolysin in the treatment of dementia,” WMW Wien. Mod. Wochenschr., 147, 426–431 (1997).Google Scholar
  17. 17.
    E. Ruther, R. Ritter, M. Apecechea, et al., “Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer’s type,” Pharmacopsychiatry, 27, No. 1, 32–40 (1994).Google Scholar
  18. 18.
    S. I. Gavrilova, I. V. Kolykhalov, N. D. Selezneva, and G. A. Zharikov, “A double-blind, placebo-controlled study of the effects of cerebrolysin on the efficacy and tolerance of subsequent cholinergic therapy in patients with Alzheimer’s disease,” Zh. Sotsial. Klin. Psikhiatr., No. 2, 41–46 (2000).Google Scholar
  19. 19.
    N. P. Gerasimov, “A double-blind, placebo-controlled study of the efficacy of cerebrolysin in Alzheimer’s disease,” Sotsial. Klin. Psikhiatr., No. 2, 35–40 (2000).Google Scholar
  20. 20.
    X. A. Alvarez, R. Cacabelos, C. Sampedro, et al., “Combination treatment in Alzheimer‘s disease: results of a randomized, controlled trial with cerebrolysin and donepezil,” Curr. Alzheimer Res., 8, No. 5, 583–591 (2011),  https://doi.org/10.2174/156720511796391863.Google Scholar
  21. 21.
    S. I. Gavrilova, Pharmacotherapy of Alzheimer’s Disease, Pulse, Moscow (2007).Google Scholar
  22. 22.
    E. Rockenstein, K. Ubhi, E. Pham, et al., “Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer’s disease,” J. Neurosci. Res., 89, No. 11, 1812–1821 (2011),  https://doi.org/10.1002/jnr.22712.Google Scholar
  23. 23.
    B. R. Kraemer, S. O. Yoon, and B. D. Carter, “The biological functions and signaling mechanisms of the p75 neurotrophin receptor,” Handb. Exp. Pharmacol., 220, 121–164 (2014),  https://doi.org/10.1007/978-3-642-45106-5_6.Google Scholar
  24. 24.
    J. K. Knowles, J. Rajadas, T. V. Nguyen, et al., “The p75 neurotrophin receptor promotes amyloid-beta (1-42)-induced neuritic dystrophy in vitro and in vivo,” J. Neurosci., 29, No. 34, 10627–10637 (2009),  https://doi.org/10.1523/JNEUROSCI.0620-09.2009.Google Scholar
  25. 25.
    X. Y. Hu, H. Y. Zhang, S. Qin, et al., “Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients,” Exp. Neurol., 178, 104–111 (2002),  https://doi.org/10.1006/exnr.2002.8018.Google Scholar
  26. 26.
    E. D. del Toro, J. M. Juiz, X. Peng, et al., “Immunocytochemical localization of the α7 subunit of the nicotinic acetylcholine receptor in the rat central nervous system,” J. Comp. Neurol., 349, No. 3, 325–342 (1994),  https://doi.org/10.1002/cne.903490302.Google Scholar
  27. 27.
    S. D. Buckingham, A. K. Jones, L. A. Brown, and D. B. Sattelle, “Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid neuroprotection,” Pharmacol. Rev., 61, No. 1, 39–61 (2009),  https://doi.org/10.1124/pr.108.000562.Google Scholar
  28. 28.
    A. V. Kamynina, E. V. Ponomareva, D. O. Koroev, et al., “Decreased levels of antibodies to a fragment of the α7-type acetylcholine receptor in serum from patients with Alzheimer’s disease,” Zh. Nevrol. Psikhiat., 115, No. 12, 128–132 (2015).Google Scholar
  29. 29.
    A. V. Kamynina, O. M. Volpina, N. I. Medvinskaya, et al., “Vaccination with peptide 173-193 of acetylcholine receptor alpha7-subunit prevents memory loss in olfactory bulbectomized mice,” J. Alzheimers Dis., 21, No. 1, 249–261 (2010),  https://doi.org/10.3233/jad-2010-091474.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • S. I. Gavrilova
    • 1
    Email author
  • O. M. Volpina
    • 2
  • I. V. Kolykhalov
    • 1
  • Ya. B. Fedorova
    • 1
  • N. D. Selezneva
    • 1
  • E. V. Ponomareva
    • 1
  • D. O. Koroev
    • 2
  • A. V. Kamynina
    • 2
  1. 1.Scientific Center for Mental HealthMoscowRussia
  2. 2.Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia

Personalised recommendations